Accolade Stock

Accolade EBITDA

Delisted·Apr 7, 2025

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Accolade (ACCD) as of Aug 5, 2026 is -69.29 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 182.30 M USD — a change of -138.01% (lower).

EBITDA

-69.29 MUSD

YoY

-138.01%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Accolade is 2026 -69.29 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Accolade was 2025 182.30 M USD. It decreases by -138.01% lower compared to the previous year.
Access this data via the Eulerpool API

Accolade Stock analysis

What does Accolade do? Accolade Inc is a US-American company based in Seattle. The company was founded in 2007 by Rajeev Singh and Mike Hilton and has since developed into a leading healthcare consulting firm. Accolade aims to make healthcare simple and affordable for everyone. The company offers a wide range of solutions to its customers. It provides services to employers, insurance companies, and health authorities. Their main focus is on supporting patients and employees in their healthcare. They also offer services to health insurance companies and health authorities. The business model of Accolade involves close collaboration between the customers and the company. Patients are supported by a "Health Assistant," who are trained professionals that help patients make the best decisions regarding their health. Factors such as finding the best providers, medication delivery, clinical tests, and alternative options are considered. Accolade's mission is to improve healthcare for everyone by providing the best solutions. The company has divided itself into several different divisions to offer its services more effectively. The various divisions of Accolade include healthcare consulting, medication management, patient access and health navigation, client support, and health optimization. Accolade has become an important healthcare service provider and has earned a good reputation in the industry. The company is known for providing comprehensive and high-quality services that focus on individual patient care. When it comes to achieving improvements in care and the entire healthcare system, Accolade is an important partner that helps companies and individuals achieve their goals and lead healthier lives. Accolade is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accolade stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Accolade is -69.29 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Accolade changed from 182.30 M USD to -69.29 M USD, representing a -138.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Accolade since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Accolade historically and in real time.

Access this data via the Eulerpool API

Income Statement — Accolade

All Key Metrics — Accolade